BioCentury
ARTICLE | Company News

Arrowhead prunes pipeline over toxicity concerns

November 30, 2016 12:35 AM UTC

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) sank $2.63 (60%) to $1.76 in early after-hours trading after it said will discontinue development of all programs using its EX1 liver-targeted, IV delivery vehicle for its RNA therapies. The cuts include HBV candidates ARC-520 and ARC-521, as well as alpha-antitrypsin deficiency (AATD) candidate ARC-AAT.

Earlier this month, FDA placed a clinical hold on the Phase IIb Heparc-2004 trial of ARC-520 to treat HBV after deaths occurred in a non-human primate toxicology study that included high doses of EX1. On Tuesday, Arrowhead said that resolving the hold would involve "substantial delays" (see BioCentury Extra, Nov. 9)...

BCIQ Company Profiles

Arrowhead Pharmaceuticals Inc.